0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover322.41%IV-150.63%PremiumOct 18, 2024Expiry Date1.20Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8559Delta0.4390Gamma0.67Leverage Ratio-0.0037Theta-0.0006Rho-0.57Eff Leverage0.0004Vega
Sangamo Therapeutics Stock Discussion
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Gene Editi
https://www.moomoo.com/t/news/post/43596799/BYnzVJBmba
Bought big Friday, looks like I made the right call. GLTA
No comment yet